Otorrhea bacterial profile, epidemiology before widespread use of the third-generation pneumococcal conjugate vaccine in French children, a prospective study from 2015 to 2023 - 01/09/23
, Emmanuelle Varon e, Philippe Bidet f, g, Stéphane Béchet a, d, Christophe Batard a, d, Alain Wollner a, d, Franck Thollot a, d, Stéphane Bonacorsi f, g, Robert Cohen a, b, c, dHighlights |
• | The distribution of 852 MEF specimens from children with SPTM showed that few cases were reported during the COVID-19 pandemic. |
• | While PCV13 showed SP to be the third bacteria involved, non-PCV13 serotypes still accounted for one third of the reported cases. |
• | NTHi is the main bacteria found in infants and toddlers with complex AOM. |
• | The growing role of GAS is of concern, especially but not only in children over 3 years old. |
Abstract |
Objectives |
The aim of this study was to describe the bacterial profile of middle ear fluid from spontaneous perforation of the tympanic membrane (SPTM) prior to widespread utilization of third- generation pneumococcal conjugate vaccines (PCVs).
Patients and methods |
From October 2015 to January 2023, children with SPTM were prospectively enrolled by pediatricians.
Results |
Among the 852 children with SPTM, 73.2% were less than 3 years old; more frequently than older children, they were and suffering from complex acute otitis media (AOM) (27.9%) and conjunctivitis (13.1%). In children under 3 years of age, NT Haemophilus influenzae (49.7%) was the main otopathogen isolated, particularly in those with complex AOM (57.1%). In children over 3 years of age, Group A Streptococcus accounted for 57%. In pneumococcal cases (25.1%), serotype 3 was the main serotype isolated (16.2%), followed by 23B (15.2%).
Conclusion |
Our data from 2015 to 2023 represent a robust baseline preceding the widespread utilization of next-generation PCVs.
Le texte complet de cet article est disponible en PDF.Keywords : Otorrhea, Streptococcus pneumoniae, Group A Streptococcus, Heamophilus influenzae, Pneumococcal conjugate vaccines
Plan
Vol 53 - N° 6
Article 104738- septembre 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
